Sugar and NICE - aggressive hyperglycaemic control in ischaemic stroke and what can we learn from non-neurological intensive glucose control trials in the critically ill?
نویسندگان
چکیده
There are two lines of evidence that drove the evolution of these guidelines: (1) The weight of arguments that suggest an association between high glucose levels and detrimental outcome has substantially increased in the last few years. Observational studies, both naturalistic [8, 9] and trialassociated [10–12] , have reported higher morbidity and mortality in patients with initial hyperglycaemia. (Note that there is neither consensus as to what actually defines ‘initial’ – is it a 1-measurement baseline, continuously elevated levels within the first 24 h or other timelines? – nor is there a clear definition of when hyperglycaemia necessitates treatment [13] .) Moreover, experimental data have underlined the association. Early neuropathological animal studies provided evidence that hyperglycaemia augments morphological brain damage in acute stroke [14, 15] . Imaging studies in hyperglycaemic animals subjected to ischaemic stroke corroborated these findings: hyperglycaemia is associated with enhanced MRI diffusion-weighted imaging alterations [16] and reduced hemispheric cerebral blood volume [17] . Importantly, equivalent correlations have been established in MRI studies in human subjects. Acute hyperglycaemia is associated with reduced salvage of perfusion-impaired tissue and larger final infarct size [18, 19] . This is also true for patients treated with intravenous tissue plasminogen Hyperglycaemia is a common phenomenon after cerebral ischaemia (for that matter, after most acute medical or surgical conditions), and clinicians have certainly been itching to treat. But should we? The devil is in the details. Continuous assessment of blood glucose levels and qualified treatment are often noted to be core components of specialized stroke care [1] . Expert statements have taken a somewhat sinusoidal course when discussing the matter. In 1994, the Stroke Council of the American Heart Association said that it may be a good idea to treat hyperglycaemia in patients with stroke just as one would treat hyperglycaemia in ‘other persons with elevated blood glucose’ [2] . The guideline was substantiated in 2003, with treatment then being warranted should blood glucose levels exceed 16.6 mmol/l (300 mg/dl) [3] . Europeans were more stringent, finding that a cut-off of 10 mmol/l (180 mg/dl) would be optimal [4, 5] . The American Stroke Association followed this lead and in 2007 revised its suggestions and noted that treatment should begin above 11.1 mmol/l (200 mg/dl), possibly as low as 7.8 mmol/l (140 mg/dl) [6] . In 2008, instead of continuing on the downward track and effectively postulating fasting normoglycaemia below 5.5 mmol/l (99 mg/dl), the European Stroke Organization retained its previous recommendation of 10 mmol/l (180 mg/dl) [7] . Received: August 26, 2009 Accepted: August 26, 2009 Published online: March 30, 2010
منابع مشابه
Glycemic control in the critically ill: What have we learned since NICE-SUGAR?
Since publication of the Normoglycemia in Intensive Care Evaluation - Survival Using Glucose Algorithm Regulation trial in 2009, demonstrating increased 90-day mortality in a large cohort of critically ill patients treated with the intensive, rather than moderate blood glucose (BG) target, enthusiasm has dampened for 'tight glucose control' in intensive care units. Nevertheless, a burgeoning li...
متن کاملMortality and Glycemic Targets in the Intensive Care Unit: Another Paradigm Shift?
Within the past year, providers caring for a patient with cardiovascular disease and diabetes have been made to realize that despite the associations of hyperglycemia and cardiovascular complications, the results from the prospective studies evaluating aggressive glycemic intervention did not follow the predicted script! Specifically, the randomized clinical trials that addressed the question o...
متن کاملGlycaemic Control in the Critically Ill: What Have We Learned Since NICE-SUGAR?
Glycaemic control of the critically ill has been a topic of considerable interest in the critical care community since the publication of a single-centre randomised controlled trial (RCT) of intensive insulin therapy (IIT) targeting euglycaemia, blood glucose (BG) 80-110 mg/dL, in a population of mechanically ventilated surgical intensive care unit (ICU) patients, 63% of whom had undergone card...
متن کاملManaging post stroke hyperglycaemia: moderate glycaemic control is better? An update
Post stroke hyperglycaemia (PSH) is prevalent in acute ischaemic stroke (AIS) patients and it has been associated with a dismal outcome of death and disability. Insulin has been proven to attenuate glucose effectively in stroke patients, thus many trials over the years had studied the efficacy of intensive treatment aiming at normalization of blood sugar level in order to improve the bleak outc...
متن کاملMetformin Treatment in Hyperglycemic Critically Ill Patients: Another Challenge on the Control of Adverse Outcomes
New-onset hyperglycemia in patients admitted to intensive care units increases the risk of morbidity and mortality. Insulin resistance is frequently seen in the treatment of stress-induced hyperglycemia. Metformin, an oral anti-hyperglycemic agent, may introduce a new treatment protocol in critically ill patients with insulin-resistance hyperglycemia. Fifty-one non-diabetic traumatized patients...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Cerebrovascular diseases
دوره 29 6 شماره
صفحات -
تاریخ انتشار 2010